So far in 2019, Aurora Cannabis (ACB) has been one of the best performers in the cannabis sector. The company has a YTD (year-to-date) return of ~80%. In comparison, peer (HMMJ) Canopy Growth (WEED) has risen ~60%. Aphria (APHA) has risen nearly 70% during the same period. The company has positive momentum. Aurora Cannabis’s announcement about adding Nelson Peltz got many investors’ attention. We’ll discuss how analysts view Aurora Cannabis stock in April.
Sign up for Bagels & Stox, our witty take on the top market and investment news, straight to your inbox! Whether you’re a serious investor or just want to be informed, Bagels & Stox will be your favorite email.
As the above chart shows, the consensus recommendation from the 11 analysts covering the stock remained unchanged month-over-month at a “buy.” Among the 11 analysts, three recommended a “strong buy,” five recommended a “buy,” two recommended a “hold,” and one recommended a “sell.” None of the analysts had a “strong sell” recommendation for Aurora Cannabis.
The current consensus target price of 13.9 Canadian dollars for Aurora Cannabis was also higher than last month’s consensus target of 13.5 Canadian dollars. The company’s target has risen considerably from ~3.4 Canadian dollars a year ago. Aurora Cannabis closed at 11.9 Canadian dollars on April 8, which would leave an upside of ~16% if analysts are right.